Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab

References

• Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. The Lancet. 2016;387(10023):1094–1108. doi:10.1016/S0140-6736(15)00130-0
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Makker V, Green AK, Wenham RM, Mutch D, Davidson B, Miller DS. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecol Oncol Res Pract. 2017;4(1):19. doi:10.1186/s40661-017-0056-7
   PubMedGoogle Scholar
• Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer — viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794–798. doi:10.1056/NEJMsr1606602
   PubMed Web of Science ®Google Scholar
• Arthur RS, Kabat GC, Kim MY, et al. Metabolic syndrome and risk of endometrial cancer in postmenopausal women: a prospective study. Cancer Causes Control. 2019;30(4):355–363. doi:10.1007/s10552-019-01139-5
   PubMed Web of Science ®Google Scholar
• Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007;50(7):1365–1374. doi:10.1007/s00125-0070681-5
   PubMed Web of Science ®Google Scholar
• Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73. doi:10.1038/nature12113
   PubMed Web of Science ®Google Scholar
• González-Cao M, Moran T, Dalmau J. Update on genetic testing in gynecologic cancer. J Clin Oncol. 2022:65. 10.1200/JCO.19.00363.
   PubMedGoogle Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092. doi:10.1056/NEJMoa1801005
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–17. doi:10.1016/0090-8258(83)90111-7
   PubMed Web of Science ®Google Scholar
• Soslow RA, Tornos C, Park KJ, et al. Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the International Society of Gynecological Pathologists. Int J Gynecol Pathol. 2019;38:S64. doi:10.1097/PGP.0000000000000518
   PubMed Web of Science ®Google Scholar
• Barlin JN, Zhou Q, St. Clair CM, et al. Classification and Regression Tree (CART) analysis of endometrial carcinoma: seeing the forest for the trees. Gynecol Oncol. 2013;130(3):452–456. doi:10.1016/j.ygyno.2013.06.009
   PubMed Web of Science ®Google Scholar
• Giannone G, Tuninetti V, Ghisoni E, et al. Role of cyclin-dependent kinase inhibitors in endometrial cancer. Int J Mol Sci. 2019;20(9):2353. doi:10.3390/ijms20092353
   PubMed Web of Science ®Google Scholar
• Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol. 2014;15(7):e268–e278. doi:10.1016/S1470-2045(13)70591-6
   PubMed Web of Science ®Google Scholar
• Peters EEM, Léon-Castillo A, Hogdall E, et al. Substantial lymphovascular space invasion is an adverse prognostic factor in high-risk endometrial cancer. Int J Gynecol Pathol. 2022;41(3):227. doi:10.1097/PGP.0000000000000805
   PubMed Web of Science ®Google Scholar
• Peters EEM, León-Castillo A, Smit VTHBM, et al. Defining substantial lymphovascular space invasion in endometrial cancer. Int J Gynecol Pathol. 2022;41(3):220. doi:10.1097/PGP.0000000000000806
   PubMed Web of Science ®Google Scholar
• Oaknin A, Bosse TJ, Creutzberg CL, et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(9):860–877. doi:10.1016/j.annonc.2022.05.009
   PubMed Web of Science ®Google Scholar
• Gilks CB, Oliva E, Soslow RA. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol. 2013;37(6):874–881. doi:10.1097/PAS.0b013e31827f576a
   PubMed Web of Science ®Google Scholar
• Kommoss S, McConechy MK, Kommoss F, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29(5):1180–1188. doi:10.1093/annonc/mdy058
   PubMed Web of Science ®Google Scholar
• Stelloo E, Jansen AML, Osse EM, et al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Ann Oncol. 2017;28(1):96–102. doi:10.1093/annonc/mdw542
   PubMed Web of Science ®Google Scholar
• Creutzberg CL, Nout RA, Lybeert MLM, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4):e631–638. doi:10.1016/j.ijrobp.2011.04.013
   PubMed Web of Science ®Google Scholar
• Wortman BG, Creutzberg CL, Putter H, et al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer. 2018;119(9):1067–1074. doi:10.1038/s41416-018-0310-8
   PubMed Web of Science ®Google Scholar
• Loukovaara M, Pasanen A, Bützow R. Clinicopathologic vs. molecular integrated prognostication of endometrial carcinoma by European Guidelines. Cancers. 2022;14(3):651. doi:10.3390/cancers14030651
   PubMed Web of Science ®Google Scholar
• McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol. 2018;244(5):538549. doi:10.1002/path.5034
   Web of Science ®Google Scholar
• Stasenko M, Tunnage I, Ashley CW, et al. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Gynecol Oncol. 2020;156(1):194–202. doi:10.1016/j.ygyno.2019.10.028
   PubMed Web of Science ®Google Scholar
• Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a Phase I, single-arm study. J Immunother Cancer. 2022;10(1):e003777. doi:10.1136/jitc-2021-003777
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 Study. J Clin Oncol off J Am Soc Clin Oncol. 2020;38(1):1–10. doi:10.1200/JCO.19.02105
   PubMed Web of Science ®Google Scholar
• Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113(2):299–310. doi:10.1038/bjc.2015.190
   PubMed Web of Science ®Google Scholar
• Singh N, Piskorz AM, Bosse T, et al. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. J Pathol. 2020;250(3):336345. doi:10.1002/path.5375
   Web of Science ®Google Scholar
• Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol. 2020;38(33):3841–3850. doi:10.1200/JCO.20.01076
   PubMed Web of Science ®Google Scholar
• Llombart-Cussac A, Pérez-García JM, Bellet M, et al. Fulvestrant-Palbociclib vs LetrozolePalbociclib as initial therapy for endocrine-sensitive, hormone receptor–positive, ERBB2negative advanced breast cancer. JAMA Oncol. 2021;7(12):1–9. doi:10.1001/jamaoncol.2021.4301
   Web of Science ®Google Scholar
• Pectasides D, Pectasides E, Economopoulos T. Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev. 2007;33(2):177–190. doi:10.1016/j.ctrv.2006.10.007
   PubMed Web of Science ®Google Scholar
• Ethier JL, Desautels DN, Amir E, MacKay H. Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecol Oncol. 2017;147(1):158–166. doi:10.1016/j.ygyno.2017.07.002
   PubMed Web of Science ®Google Scholar
• Mileshkin L, Edmondson R, O’Connell RL, et al. Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: the PARAGON trial – ANZGOG 0903. Gynecol Oncol. 2019;154(1):29–37. doi:10.1016/j.ygyno.2019.05.007
   PubMed Web of Science ®Google Scholar
• Wang Y, Tillmanns T, VanderWalde N, et al. Comparison of chemotherapy vs chemotherapy plus total hysterectomy for women with uterine cancer with distant organ metastasis. JAMA Netw Open. 2021;4(7):e2118603. doi:10.1001/jamanetworkopen.2021.18603
   PubMed Web of Science ®Google Scholar
• Landrum LM, Moore KN, Myers TKN, et al. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis. Gynecol Oncol. 2009;112(2):337–341. doi:10.1016/j.ygyno.2008.10.009
   PubMed Web of Science ®Google Scholar
• Albright BB, Monuszko KA, Kaplan SJ, et al. Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol. 2021;225(3):237.e1–237.e24. doi:10.1016/j.ajog.2021.04.254
   PubMed Web of Science ®Google Scholar
• Parmar MKB, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet Lond Engl. 2003;361(9375):2099–2106. doi:10.1016/s0140-6736(03)13718-x
   PubMed Web of Science ®Google Scholar
• Nagao S, Nishio S, Michimae H, et al. Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study. Gynecol Oncol. 2013;131(3):567–573. doi:10.1016/j.ygyno.2013.09.021
   PubMed Web of Science ®Google Scholar
• Dellinger TH, Monk BJ. Systemic therapy for recurrent endometrial cancer: a review of North American trials. Expert Rev Anticancer Ther. 2009;9(7):905–916. doi:10.1586/era.09.54
   PubMed Web of Science ®Google Scholar
• O’Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 Study. J Clin Oncol off J Am Soc Clin Oncol. 2022;40(7):752–761. doi:10.1200/JCO.21.01874
   PubMed Web of Science ®Google Scholar
• Kato Y, Tabata K, Kimura T, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019;14(2):e0212513. doi:10.1371/journal.pone.0212513
   PubMed Web of Science ®Google Scholar
• Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):711–718. doi:10.1016/S1470-2045(19)30020-8
   PubMed Web of Science ®Google Scholar
• Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437–448. doi:10.1056/NEJMoa2108330
   PubMed Web of Science ®Google Scholar
• Marth C, Tarnawski R, Tyulyandina A, et al. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. Int J Gynecol Cancer. 2022;32(1):93–100. doi:10.1136/ijgc-2021-003017
   PubMed Web of Science ®Google Scholar
• Lu L, Li Y, Luo R, Xu J, Feng J, Wang M. Prognostic and clinicopathological role of PD-L1 in endometrial cancer: a meta-analysis. Front Oncol. 2020;1:334.
   Google Scholar
• Ott PA, Bang YJ, Berton-Rigaud D, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: results from the KEYNOTE-028 Study. J Clin Oncol. 2017;35(22):2535–2541. doi:10.1200/JCO.2017.72.5952
   PubMed Web of Science ®Google Scholar
• Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib Plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol off J Am Soc Clin Oncol. 2020;38(26):29812992. doi:10.1200/JCO.19.02627
   Web of Science ®Google Scholar
• Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–1365. doi:10.1016/S1470-2045(20)30445-9
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. doi:10.1186/s13073-017-0424-2
   PubMed Web of Science ®Google Scholar
• Goodman AM, Sokol ES, Frampton GM, Lippman SM, Kurzrock R. Microsatellite-stable tumors with high mutational burden benefit from immunotherapy. Cancer Immunol Res. 2019;7(10):1570–1573. doi:10.1158/2326-6066.CIR-19-0149
   PubMed Web of Science ®Google Scholar
• Palomero J, Panisello C, Lozano-Rabella M, et al. Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer. J Immunother Cancer. 2022;10(12):e005443. doi:10.1136/jitc-2022-005443
   PubMed Web of Science ®Google Scholar
• Jiang T, Chen X, Su C, Ren S, Zhou C. Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes. J Cancer. 2020;11(4):776–780. doi:10.7150/jca.41296
   PubMed Web of Science ®Google Scholar
• De Leo A, Ravegnini G, Musiani F, et al. Relevance of ARID1A mutations in endometrial carcinomas. Diagnostics. 2022;12(3):592. doi:10.3390/diagnostics12030592
   Web of Science ®Google Scholar
• Roque DM, Bellone S, Siegel ER, et al. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). J Clin Oncol. 2021;39(15_suppl):5523. doi:10.1200/JCO.2021.39.15_suppl.5523
   Web of Science ®Google Scholar
• de Biasi AR, Villena-Vargas J, Adusumilli PS. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res. 2014;20(21):5384–5391. doi:10.1158/1078-0432.CCR-14-1298
   PubMed Web of Science ®Google Scholar
• Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385(20):1856–1867. doi:10.1056/NEJMoa2112435
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051. doi:10.1056/NEJMoa1810865
   PubMed Web of Science ®Google Scholar
• Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70(15):6171–6180. doi:10.1158/0008-5472.CAN-10-0153
   PubMed Web of Science ®Google Scholar
• Koshkin VS, Sonpavde GP, Hwang C, et al. Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): preliminary safety results from a phase 2 study. J Clin Oncol. 2022;40(6_suppl):501. doi:10.1200/JCO.2022.40.6_suppl.501
   Web of Science ®Google Scholar